Skip to content
Evevident
Original paper
2011NEJMCardiology

EMPHASIS-HF

Eplerenone in patients with systolic heart failure and mild symptoms

RCTHFrEF

On this page

Overview

Eplerenone improved outcomes in mildly symptomatic HFrEF, extending MRA benefit beyond severe HF.

Clinical takeaway

EMPHASIS-HF showed that mineralocorticoid receptor antagonists benefit NYHA II HFrEF patients, complementing RALES in severe HFrEF.

Key result

CV death or HF hospitalization was reduced with eplerenone; HR 0.63.

Practice impact

MRAs became standard for eligible patients with symptomatic HFrEF, not only advanced symptoms.

Evidence

Study design

Randomized, double-blind, placebo-controlled trial stopped early for benefit.

Enrollment

2,737

Follow-up

Median 21 months.

Geography

Multinational

Clinical question

Does eplerenone improve outcomes in patients with systolic heart failure and mild symptoms?

Population

  • Patients with NYHA class II heart failure and left ventricular ejection fraction <=35% on recommended therapy.

Intervention

Eplerenone.

Comparator

Placebo.

Primary outcome

Composite of cardiovascular death or hospitalization for heart failure.

Eplerenone reduced cardiovascular death or heart-failure hospitalization in mildly symptomatic HFrEF.

Hazard ratio / 0.63 / CI 95% CI 0.54-0.74 / p=<0.001

Key results

  • Primary composite: 18.3% with eplerenone vs 25.9% with placebo; HR 0.63.
  • All-cause mortality was reduced.
  • Hospitalization for heart failure was reduced.

Harms

  • Hyperkalemia was more common with eplerenone.
  • Gynecomastia is less common with eplerenone than spironolactone but renal and potassium monitoring remain essential.

Clinical Use

When to cite

  • When adding an MRA to a patient with mild but symptomatic HFrEF.

Practice impact

  • Extended MRA use to eligible NYHA II HFrEF patients.

Applicability

  • Stable HFrEF patients with adequate renal function and acceptable potassium.

Limitations

  • Pre-ARNI and pre-SGLT2 era.
  • Requires careful lab monitoring and does not apply to advanced kidney dysfunction or baseline hyperkalemia.

Common misinterpretations

  • Do not confuse trial eligibility with blanket MRA use; potassium and renal thresholds matter.

Related evidence

RALES - Earlier TrialPARADIGM-HF - Same Disease

Citation

Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492

Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms.